BTK Inhibitor Shows Potential in Immune Thrombocytopenia

(MedPage Today) -- An investigational oral Bruton's tyrosine kinase (BTK) inhibitor was tolerable and yielded rapid and durable responses in pretreated patients with immune thrombocytopenia (ITP), according to results of an open-label phase I/II...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news